Abstract

To observe the therapeutic effect of pediatric Chiqiao Qingre granules in conjunction with oseltamivir phosphate granules in treating influenza A. A total of 300 pediatric patients diagnosed with influenza A, admitted to Nanjing Pukou District Traditional Chinese Medicine Hospital from February 2022 to February 2023, were randomly allocated into two groups; the control group and the observation group (150 cases in each group). Routine treatments, including anti-infection measures, cough relief, and correction of acid-base balance, were administered to both groups. Alongside these treatments, the control group received phosphoric oseltamivir granules, while the observation group received a combination of Chiqiao Qingre granules and oseltamivir phosphate granules for the duration of 7 consecutive days. Clinical efficacy, relief duration of nasal congestion, cough, fever, and pharyngeal congestion, as well as the concentrations of C-reactive protein and serum amyloid A, were investigated and compared between the two groups in this study. Moreover, adverse reactions that occurred during the treatment period were closely monitored and recorded. Following treatment, the observation group exhibited a substantially higher total effective rate of 96.67 % in comparison to the control group’s rate of 79.67 %, thus indicating a statistically significant difference (p<0.05). The observation group exhibited remarkably shorter durations of nasal congestion, cough, fever, and pharyngeal congestion relief as opposed to the control group (p<0.05). Following the treatment, decreased levels of both C-reactive protein and serum amyloid A were observed in both groups, with the observation group exhibiting significantly lower levels compared to the control group (p<0.05). There were no notable distinctions observed in the incidence of adverse reactions between the two groups (p>0.05). The simultaneous administration of pediatric Chiqiao Qingre granules and oseltamivir phosphate granules showcased remarkable therapeutic efficacy and an excellent safety profile in treating influenza A.